Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL. Clouthier DL, et al. Among authors: brooks dg. J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0. J Immunother Cancer. 2019. PMID: 30867072 Free PMC article. Clinical Trial.
Type I Interferon in Chronic Virus Infection and Cancer.
Snell LM, McGaha TL, Brooks DG. Snell LM, et al. Among authors: brooks dg. Trends Immunol. 2017 Aug;38(8):542-557. doi: 10.1016/j.it.2017.05.005. Epub 2017 May 31. Trends Immunol. 2017. PMID: 28579323 Free PMC article. Review.
Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.
Gadalla R, Noamani B, MacLeod BL, Dickson RJ, Guo M, Xu W, Lukhele S, Elsaesser HJ, Razak ARA, Hirano N, McGaha TL, Wang B, Butler M, Guidos CJ, Ohashi PS, Siu LL, Brooks DG. Gadalla R, et al. Among authors: brooks dg. Front Oncol. 2019 May 17;9:415. doi: 10.3389/fonc.2019.00415. eCollection 2019. Front Oncol. 2019. PMID: 31165047 Free PMC article.
GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.
Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TDS, Ugel S, Tsirigos A, Bronte V, Munn DH, Pugh TJ, De Carvalho DD, Butler MO, Ohashi PS, Brooks DG, McGaha TL. Halaby MJ, et al. Among authors: brooks dg. Sci Immunol. 2019 Dec 13;4(42):eaax8189. doi: 10.1126/sciimmunol.aax8189. Sci Immunol. 2019. PMID: 31836669 Free PMC article.
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ. Cindy Yang SY, et al. Among authors: brooks dg. Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7. Nat Commun. 2021. PMID: 34446728 Free PMC article. Clinical Trial.
Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection.
Snell LM, Xu W, Abd-Rabbo D, Boukhaled G, Guo M, Macleod BL, Elsaesser HJ, Hezaveh K, Alsahafi N, Lukhele S, Nejat S, Prabhakaran R, Epelman S, McGaha TL, Brooks DG. Snell LM, et al. Among authors: brooks dg. Nat Immunol. 2021 Dec;22(12):1524-1537. doi: 10.1038/s41590-021-01060-7. Epub 2021 Nov 18. Nat Immunol. 2021. PMID: 34795443 Free PMC article.
Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity.
Hezaveh K, Shinde RS, Klötgen A, Halaby MJ, Lamorte S, Ciudad MT, Quevedo R, Neufeld L, Liu ZQ, Jin R, Grünwald BT, Foerster EG, Chaharlangi D, Guo M, Makhijani P, Zhang X, Pugh TJ, Pinto DM, Co IL, McGuigan AP, Jang GH, Khokha R, Ohashi PS, O'Kane GM, Gallinger S, Navarre WW, Maughan H, Philpott DJ, Brooks DG, McGaha TL. Hezaveh K, et al. Among authors: brooks dg. Immunity. 2022 Feb 8;55(2):324-340.e8. doi: 10.1016/j.immuni.2022.01.006. Immunity. 2022. PMID: 35139353 Free PMC article.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF. Lheureux S, et al. Among authors: brooks dg. J Immunother Cancer. 2022 Mar;10(3):e004233. doi: 10.1136/jitc-2021-004233. J Immunother Cancer. 2022. PMID: 35288469 Free PMC article. Clinical Trial.
111 results